



Blake, Cassels & Graydon LLP
Barristers & Solicitors
Patent & Trademark Agents
1133 Melville Street
Suite 3500, The Stack
Vancouver, B.C. V6E 4E5 Canada
Tel: 604-631-3300 Fax: 604-631-3309

December 19, 2024

VIA SEDAR+

British Columbia Securities Commission, as principal regulator
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
Ontario Securities Commission
Autorité des marchés financiers
Nova Scotia Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Prince Edward Island Office of the Superintendent of Securities
Securities, Service Newfoundland and Labrador
Office of the Superintendent of Securities (Northwest Territories)
Office of the Yukon Superintendent of Securities
Office of the Superintendent of Securities (Nunavut)

Dear Sirs/Mesdames:

Re: NervGen Pharma Corp. (the “Company”) – Prospectus Supplement dated December 19, 2024

We refer to the prospectus supplement dated December 19, 2024 (the “**Prospectus Supplement**”) to the short form base shelf prospectus dated November 25, 2024 of the Company with respect to the issuance of common shares in the capital of the Company, as described in the Prospectus Supplement.

We hereby consent to the references to our firm name under the heading “*Legal Matters and Interests of Experts*” in the Prospectus Supplement, and to the use of and references to our name and our legal opinion under the heading “*Eligibility for Investment*” in the Prospectus Supplement.

We confirm that we have read the Prospectus Supplement and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from our legal opinions referred to above or that are within our knowledge as a result of the services that we performed in connection with such opinion.

Yours truly,

(signed) “*Blake, Cassels & Graydon LLP*”

Blake, Cassels & Graydon LLP